Neuralgia Clinical Trial
Official title:
Effects of Pennsaid on Clinical Neuropathic Pain
The purpose of this study is to see if the drug Pennsaid (Diclofenac) can help reduce pain
felt by people with chronic nerve pain. The drug will be used 2-4 times each day for 2
weeks.
The U.S. Food and Drug Administration (FDA) has approved Pennsaid to treat osteoarthritis
(bone pain), but the FDA has not approved Pennsaid to treat neuropathic (nerve) pain.
The research study will compare Pennsaid to placebo.
Status | Active, not recruiting |
Enrollment | 48 |
Est. completion date | December 2015 |
Est. primary completion date | February 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: 1. Subject will be between 18 and 80 years of age. 2. Subject has not been on Pennsaid or other topical non-steroid anti-inflammatory drugs for at least one month. 3. Subject agrees to make no change in his/her current pain medications during the entire study period. This requirement will ensure that valid comparisons of primary and secondary measures can be made before and after the study. 4. Subject has a VAS pain score of 4 or above at the beginning of the study. 5. Subject has had a neuropathic pain condition such as those listed above for at least three months. This requirement is to avoid clinical uncertainty from an unstable pain condition and to minimize the study variation. 6. Female subjects of childbearing age must have a negative urine pregnancy test at the initial visit. Exclusion Criteria: 1. Subject has documented severe liver or renal disease that will affect the elimination of Pennsaid or is subject to the adverse effect of Pennsaid on these organs. (Renal dysfunction is defined as eGFR < 60. Hepatic dysfunction is defined as LFTs = 3X ULN.) 2. Subject has pending litigation related to the neuropathic pain condition. 3. Subject has active skin lesion or open wound at the site of Pennsaid application (e.g., active shingles with skin lesions). 4. Subject is pregnant or lactating. 5. Subject has scar tissue or sensory deficit at the site of QST. 6. Subject is allergic to diclofenac or has cross-sensitivity to other non-steroid anti-inflammatory drugs. 7. Subject has a positive urine (illicit) drug test. 8. Subjects who experience asthma, urticaria or an allergic type reaction when taking aspirin or NSAIDs. 9. Subjects undergoing coronary artery bypass surgery. 10. Subject with a known history of cardiovascular disease, ulcer, gastrointestinal bleed or impaired renal function. 11. Subjects currently using NSAIDS. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Country | Name | City | State |
---|---|---|---|
United States | MGH Center for Translational Pain Research | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Massachusetts General Hospital |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Effect of Pennsaid on Clinical Neuropathic Pain | Four times throughout the study the subject will fill out questionnaires, SF-36s, and take QSTs. | Five weeks. | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04066933 -
Forms of Cervical Brachial Syndrome Treated With Plasma Concentrate Enriched for A2M
|
||
Completed |
NCT01202227 -
An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain
|
Phase 3 | |
Completed |
NCT00922987 -
Clinical Study With Lyrica In Patients Suffering From Epilepsy
|
||
Terminated |
NCT00964990 -
A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)
|
Phase 2 | |
Recruiting |
NCT00740571 -
Amitriptyline or Pregabalin to Treat Neuropathic Pain in Incurable Cancer
|
Phase 3 | |
Terminated |
NCT02747758 -
Transcranial Direct Current Stimulation (tDCS) in Chronic Neuropathy
|
N/A | |
Completed |
NCT05464199 -
Home-based EEG Neurofeedback for Chronic Neuropathic Pain
|
Phase 1 | |
Completed |
NCT02490436 -
Novel Treatment Option for Neuropathic Pain
|
Phase 2 | |
Completed |
NCT01974791 -
GET Living: Graded Exposure Treatment for Children and Adolescents With Chronic Pain
|
N/A | |
Completed |
NCT01279018 -
Persistent Pain After Breast Cancer Treatment With Docetaxel
|
N/A | |
Not yet recruiting |
NCT00944502 -
To Evaluate the Efficacy and Tolerability of the Use of Vitatonus Dexa Compared to Dexamethasone in Patients With Neuralgia of Various Origins
|
Phase 3 | |
Completed |
NCT02957851 -
EMONO for the Treatment of Peripheral Neuropathic Pain
|
Phase 2 | |
Completed |
NCT02180880 -
Symptom Based Treatment of Neuropathic Pain
|
Phase 4 | |
Completed |
NCT00631943 -
A Study to Evaluate the Efficacy and Safety of Pregabalin (Lyrica) for the Treatment of Nerve Pain
|
Phase 3 | |
Completed |
NCT03973983 -
Comparison of Ultrasound-guided Transgluteal and Finger-guided Transvaginal Pudendal Nerve Block Techniques
|
N/A | |
Terminated |
NCT03296111 -
Patients With Ocular Neuropathic Pain: Description of Pain and Impact on Their Quality of Life
|
||
Not yet recruiting |
NCT06398847 -
Virtual Reality (VR) Self-Hypnosis Software
|
N/A | |
Terminated |
NCT02460107 -
Botulinum Toxin Type A for Neuropathic Pain in Patients With Diabetic Peripheral Polyneuropathy
|
Early Phase 1 | |
Recruiting |
NCT01788410 -
MRI-Guided Cryoablation to Alleviate Pain in Head, Neck and Spine
|
||
Completed |
NCT01855594 -
Study to Evaluate the Efficacy of Lithium Carbonate in Spinal Cord Injury Patients With Neuropathic Pain
|
Phase 2 |